Propanc Health Group Corp (OTCMKTS:PPCH) a growing healthcare firm reported that it finalized a biomarker discovery deal with Adaptive Biotechnologies. Under the deal, Adaptive will use company’s patented immune profiling test, the immunoSEQ Assay, to allow an in-depth portrayal of the immune response to ailments being investigated in both the pre-clinical stage and in later clinical development measures focused on Propanc’s “PRP” therapeutic.
The study of immune responses in outside the cell tumor microenvironment, where Propanc’s drug is thought to have a key role, may identify patient enrolments more likely to respond to treatment depending on their immune status.
The CEO James Nathanielsz said that Propanc management is delighted to finalize the research deal with Adaptive Biotechnologies. The company is right at the forefront in the immuno-oncology industry. Propanc’s team look forward to know more about PRP, its mechanisms, its impact on the region around the cancer cell and more importantly subjects’ response to treatment. All these factors will boost the development initiatives of PRP and the ongoing research discovery plans.
Chad Robins, the President, Co-Founder and CEO of Adaptive, said that as a leader firm in immuno sequencing, they are set to work closely with firms like Propanc to support discovery and innovations in cancer therapeutics. The technology continues to shows the significance of revealing the adaptive immune system and its role in understanding a patient’s immune response to new treatments.
Last month has been a strong month for Propanc Health Group Corp (OTCMKTS:PPCH). The stock price traded close to $0.06 in the first week of last month and from there on climbed up to record a high over $0.125. In last trading session, the stock price of Propanc declined over 2% to close the trading session at $0.0870. The decline came at a share volume of 3.04 million compared to average share volume of 14.22 million.